ACADIA PHARMACEUTICALS INC. (ACAD) Return on equity 2016–2025
ACADIA PHARMACEUTICALS INC. (ACAD) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
31.9%FY2025 · since FY2016: -52.4% → 31.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 31.9% | +1.0 pp |
| FY2024 | 30.9% | +45.1 pp |
| FY2023 | -14.2% | +39.7 pp |
| FY2022 | -53.9% | -22.9 pp |
| FY2021 | -31.0% | +13.9 pp |
| FY2020 | -44.9% | -11.3 pp |
| FY2019 | -33.7% | +17.5 pp |
| FY2018 | -51.2% | +35.1 pp |
| FY2017 | -86.3% | -34.0 pp |
| FY2016 | -52.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ACAD financial trends
ACAD RevenueACAD Net incomeACAD Net marginACAD Gross profitACAD Gross marginACAD Operating incomeACAD Operating marginACAD Operating cash flowACAD Free cash flowACAD Capital expendituresACAD Stock buybacksACAD Dividends paidACAD Total assetsACAD Total liabilitiesACAD Shareholders’ equityACAD overview →